147 related articles for article (PubMed ID: 1592346)
41. [The effects of the cholesterol synthesis inhibitor simvastatin in patients with hypercholesterolemia with and without diabetes mellitus].
van Deursen RT; Nieuwenhuijzen Kruseman AC; Degenaar CP; Wolffenbuttel BH
Ned Tijdschr Geneeskd; 1990 Nov; 134(44):2142-6. PubMed ID: 2247172
[TBL] [Abstract][Full Text] [Related]
42. [Efficacy and tolerability of simvastatin and omega-3 fatty acid combination in patients with coronary disease, hypercholesterolemia and hypertriglyceridemia].
Tomei R; Rossi L; Carbonieri E; Franceschini L; Cemin C; Ghebremariam-Tesfau K; Zardini P
Cardiologia; 1993 Dec; 38(12):773-8. PubMed ID: 8200011
[TBL] [Abstract][Full Text] [Related]
43. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
Hsu I; Spinler SA; Johnson NE
Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
[TBL] [Abstract][Full Text] [Related]
44. Simvastatin therapy for hypercholesterolaemia in patients with coronary heart disease.
French JK; White HD; Greaves SC
N Z Med J; 1990 Feb; 103(883):41-3. PubMed ID: 2304688
[TBL] [Abstract][Full Text] [Related]
45. [Simvastatin in the treatment of hypercholesterolemia].
Cigala O; Pancallo MT; Della Valle M; Marasco A; Malarbi AL
Clin Ter; 1991 Jun; 137(5):333-7. PubMed ID: 1832606
[TBL] [Abstract][Full Text] [Related]
46. [Simvastatin versus gemfibrozil in the treatment of primary hypercholesterolemia in hypertensive patients treated with hydrochlorothiazide].
Berioli S; Bentivoglio M; Conti R; Osanna RA; Savino K; Zollino L; Corea L
Cardiologia; 1990 Apr; 35(4):335-40. PubMed ID: 2245435
[TBL] [Abstract][Full Text] [Related]
47. Influence of ursodeoxycholic acid on biliary lipids.
Roda E; Cipolla A; Salzetta A; Marchetto S; Pezzoli A; Accogli E; Novelli V; Polimeni C; Cerrè C; Mazzella G
Scand J Gastroenterol Suppl; 1994; 204():16-8. PubMed ID: 7824872
[TBL] [Abstract][Full Text] [Related]
48. [Therapy of hypercholesterolemia after heart transplantation with the HMG-CoA reductase inhibitor simvastatin in long-term follow-up].
Wenke K; Thiery J; Meiser B; Arndtz N; Seidel D; Reichart B
Z Kardiol; 1995 Feb; 84(2):130-6. PubMed ID: 7717016
[TBL] [Abstract][Full Text] [Related]
49. Effects of simvastatin and probucol in hypercholesterolemia (Simvastatin Multicenter Study Group II).
Pietro DA; Alexander S; Mantell G; Staggers JE; Cook TJ
Am J Cardiol; 1989 Mar; 63(11):682-6. PubMed ID: 2646895
[TBL] [Abstract][Full Text] [Related]
50. HMG CoA reductase inhibitors as lipid-lowering agents: five years experience with lovastatin and an appraisal of simvastatin and pravastatin.
Maher VM; Thompson GR
Q J Med; 1990 Feb; 74(274):165-75. PubMed ID: 2111917
[TBL] [Abstract][Full Text] [Related]
51. Crossover trial of simvastatin versus pravastatin in patients with primary hypercholesterolemia.
Sasaki S; Sawada S; Nakata T; Itoh H; Takeda K; Nakagawa M; Kuriyama K
J Cardiovasc Pharmacol; 1997 Jul; 30(1):142-7. PubMed ID: 9268234
[TBL] [Abstract][Full Text] [Related]
52. [HMG-CoA reductase inhibitors in familial hypercholesterolemia. Therapy with simvastatin alone and in combination with cholestyramine in low dosage; a report of 2 years experiences].
Geisel J; Oette K; Burrichter H
Fortschr Med; 1990 Feb; 108(4):71-2, 75-6. PubMed ID: 2312032
[TBL] [Abstract][Full Text] [Related]
53. Statin therapy in clinical practice: new developments.
Shepherd J
Curr Opin Lipidol; 1995 Oct; 6(5):254-5. PubMed ID: 8520846
[No Abstract] [Full Text] [Related]
54. Effect of ursodeoxycholic acid on the kinetics of cholic acid and chenodeoxycholic acid in patients with primary sclerosing cholangitis.
Rudolph G; Endele R; Senn M; Stiehl A
Hepatology; 1993 Jun; 17(6):1028-32. PubMed ID: 8514251
[TBL] [Abstract][Full Text] [Related]
55. Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women.
Darling GM; Johns JA; McCloud PI; Davis SR
N Engl J Med; 1997 Aug; 337(9):595-601. PubMed ID: 9271481
[TBL] [Abstract][Full Text] [Related]
56. Effect of 7-ketolithocholic acid on bile acid metabolism in humans.
Salen G; Verga D; Batta AK; Tint GS; Shefer S
Gastroenterology; 1982 Aug; 83(2):341-7. PubMed ID: 7084613
[TBL] [Abstract][Full Text] [Related]
57. Low-dose ursodeoxycholic acid prolongs cholesterol nucleation time in gallbladder bile of patients with cholesterol gallstones.
Jüngst D; Brenner G; Pratschke E; Paumgartner G
J Hepatol; 1989 Jan; 8(1):1-6. PubMed ID: 2921499
[TBL] [Abstract][Full Text] [Related]
58. New 6-substituted bile acids: physico-chemical and biological properties of 6 alpha-methyl ursodeoxycholic acid and 6 alpha-methyl-7-epicholic acid.
Roda A; Pellicciari R; Cerrè C; Polimeni C; Sadeghpour B; Marinozzi M; Forti GC; Sapigni E
J Lipid Res; 1994 Dec; 35(12):2268-79. PubMed ID: 7897324
[TBL] [Abstract][Full Text] [Related]
59. [Extended worldwide experience. HMG-CoA reductase inhibitors: lovastatin and simvastatin].
Mantell G
Therapie; 1992; 47(2):161-4. PubMed ID: 1412144
[TBL] [Abstract][Full Text] [Related]
60. Treatment of primary hypercholesterolaemia with simvastatin. New Zealand multicentre evaluation.
Lintott CJ; Scott RS; Sharpe DN; Nye ER; Charleson H; French JK; White HD; Reuben S; Maling TJ; Lewis GR
Med J Aust; 1991 Oct; 155(7):433-6. PubMed ID: 1921811
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
